PAZOPANIB vs SORAFENIB

Compare PAZOPANIB (Pazopanib) and SORAFENIB (sorafenib) — clinical data, side effects, and patient experiences.

PAZOPANIB

Pazopanib · Targeted Cancer Therapy

How it works

12.1 Mechanism of Action Pazopanib is a multi-tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor r...

Approved for

See full prescribing information

OralTablet

SORAFENIB

sorafenib · Targeted Cancer Therapy

How it works

Targeted Cancer Therapy agent

Approved for

Sorafenib tablets are a kinase inhibitor indicated for the treatment of Unresectable hepatocellular carcinoma(1.1) Locally recurrent or metastatic

progressive

differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.

OralTablet

Quick Comparison

PAZOPANIBSORAFENIB

Drug Class

Targeted Cancer Therapy

Route

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

PAZOPANIB

Diarrhea

>10%

Fatigue

1-10%

Nausea

1-10%

Drug Not Working

1-10%

Decreased Appetite

1-10%

Vomiting

1-10%

High Blood Pressure

0.1-1%

Weakness

0.1-1%

SORAFENIB

Diarrhea

>10%

Fatigue

1-10%

Rash

1-10%

Decreased Appetite

1-10%

Nausea

1-10%

Weakness

1-10%

High Blood Pressure

1-10%

Fever

0.1-1%

FDA Warnings

PAZOPANIB

5 WARNINGS AND PRECAUTIONS Hepatic Toxicity: Severe and fatal hepatotoxicity has occurred
1 ) QT Prolongation and Torsades de Pointes: Monitor patients who are at significant risk of developing QT interval prolongation
Conduct baseline and periodic evaluation of LVEF in patients at risk of cardiac dysfunction
3 ) Hemorrhagic Events: Fatal hemorrhagic events have occurred

SORAFENIB

5) Risk of Impaired Wound Healing: Withhold sorafenib tablets for at least 10 days prior to elective surgery
7) QT Prolongation: Monitor electrocardiograms and electrolytes in patients at increased risk for ventricular arrhythmias
Advise patients of the potential risk to a fetus and to use effective contraception
2 Hemorrhage An increased risk of bleeding may occur following sorafenib tablets administration

Clinical Trial Data

No head-to-head clinical studies found for PAZOPANIB vs SORAFENIB.

PAZOPANIB vs SORAFENIB: What You Should Know

Key Differences

Both PAZOPANIB and SORAFENIB belong to the Targeted Cancer Therapy class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients.

Safety Considerations

PAZOPANIB carries 4 FDA warnings. SORAFENIB carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

LORLATINIB vs SORAFENIB→LORLATINIB vs PAZOPANIB→GEFITINIB vs SORAFENIB→LAROTRECTINIB vs SORAFENIB→IBRUTINIB vs SORAFENIB→BRIGATINIB vs SORAFENIB→

Loading comparison data...

PAZOPANIB vs SORAFENIB

Compare PAZOPANIB (Pazopanib) and SORAFENIB (sorafenib) — clinical data, side effects, and patient experiences.

PAZOPANIB

Pazopanib · Targeted Cancer Therapy

How it works

12.1 Mechanism of Action Pazopanib is a multi-tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor r...

Approved for

See full prescribing information

OralTablet

SORAFENIB

sorafenib · Targeted Cancer Therapy

How it works

Targeted Cancer Therapy agent

Approved for

Sorafenib tablets are a kinase inhibitor indicated for the treatment of Unresectable hepatocellular carcinoma(1.1) Locally recurrent or metastatic

progressive

differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.

OralTablet

Quick Comparison

PAZOPANIBSORAFENIB

Drug Class

Targeted Cancer Therapy

Route

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

PAZOPANIB

Diarrhea

>10%

Fatigue

1-10%

Nausea

1-10%

Drug Not Working

1-10%

Decreased Appetite

1-10%

Vomiting

1-10%

High Blood Pressure

0.1-1%

Weakness

0.1-1%

SORAFENIB

Diarrhea

>10%

Fatigue

1-10%

Rash

1-10%

Decreased Appetite

1-10%

Nausea

1-10%

Weakness

1-10%

High Blood Pressure

1-10%

Fever

0.1-1%

FDA Warnings

PAZOPANIB

5 WARNINGS AND PRECAUTIONS Hepatic Toxicity: Severe and fatal hepatotoxicity has occurred
1 ) QT Prolongation and Torsades de Pointes: Monitor patients who are at significant risk of developing QT interval prolongation
Conduct baseline and periodic evaluation of LVEF in patients at risk of cardiac dysfunction
3 ) Hemorrhagic Events: Fatal hemorrhagic events have occurred

SORAFENIB

5) Risk of Impaired Wound Healing: Withhold sorafenib tablets for at least 10 days prior to elective surgery
7) QT Prolongation: Monitor electrocardiograms and electrolytes in patients at increased risk for ventricular arrhythmias
Advise patients of the potential risk to a fetus and to use effective contraception
2 Hemorrhage An increased risk of bleeding may occur following sorafenib tablets administration

Clinical Trial Data

No head-to-head clinical studies found for PAZOPANIB vs SORAFENIB.

PAZOPANIB vs SORAFENIB: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.